New Hampshire Trust Sells 8,836 Shares of Pfizer Inc. (NYSE:PFE)

New Hampshire Trust reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 31.1% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 19,580 shares of the biopharmaceutical company’s stock after selling 8,836 shares during the period. New Hampshire Trust’s holdings in Pfizer were worth $519,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently modified their holdings of PFE. Bonness Enterprises Inc. boosted its position in shares of Pfizer by 3.4% during the fourth quarter. Bonness Enterprises Inc. now owns 161,508 shares of the biopharmaceutical company’s stock valued at $4,285,000 after buying an additional 5,300 shares during the last quarter. Amplius Wealth Advisors LLC lifted its stake in Pfizer by 80.7% during the 4th quarter. Amplius Wealth Advisors LLC now owns 46,823 shares of the biopharmaceutical company’s stock valued at $1,242,000 after acquiring an additional 20,911 shares in the last quarter. Cove Private Wealth LLC boosted its holdings in Pfizer by 693.5% during the 4th quarter. Cove Private Wealth LLC now owns 92,280 shares of the biopharmaceutical company’s stock worth $2,448,000 after acquiring an additional 80,650 shares during the last quarter. FLC Capital Advisors grew its stake in shares of Pfizer by 22.8% in the 4th quarter. FLC Capital Advisors now owns 47,611 shares of the biopharmaceutical company’s stock worth $1,263,000 after acquiring an additional 8,839 shares in the last quarter. Finally, SFG Wealth Management LLC. purchased a new stake in shares of Pfizer in the fourth quarter valued at about $228,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Guggenheim reduced their price objective on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Truist Financial reduced their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Sanford C. Bernstein initiated coverage on Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective for the company. Finally, Wolfe Research started coverage on Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 target price on the stock. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

Pfizer Stock Performance

Shares of PFE stock opened at $26.30 on Tuesday. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The stock has a market capitalization of $149.06 billion, a P/E ratio of 35.55, a PEG ratio of 0.63 and a beta of 0.64. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm’s 50 day moving average is $26.08 and its 200 day moving average is $27.99.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. During the same period in the previous year, the company posted ($0.17) EPS. The firm’s revenue for the quarter was up 31.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.54%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is presently 227.03%.

Insider Buying and Selling

In related news, Director Scott Gottlieb purchased 1,000 shares of the business’s stock in a transaction on Wednesday, October 30th. The stock was acquired at an average price of $28.24 per share, with a total value of $28,240.00. Following the purchase, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This represents a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is owned by company insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.